Deutsche Bank
CBIO

Deutsche Bank’s Crescent Biopharma CBIO Stock Holding History

Deutsche Bank’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-352
Closed -$106K – 4678
2021
Q1 		$106K Sell
352
-4
-1% -$1.43K ﹤0.01% 3952
2020
Q4 		$133K Buy
356
+169
+90% +$59.2K ﹤0.01% 3693
2020
Q3 		$58K Buy
187
+22
+13% +$8.41K ﹤0.01% 3811
2020
Q2 		$62K Buy
165
+50
+43% +$14.2K ﹤0.01% 3706
2020
Q1 		$26K Sell
115
-7
-6% -$2.68K ﹤0.01% 3837
2019
Q4 		$63K Buy
122
+27
+28% +$14.6K ﹤0.01% 3844
2019
Q3 		$40K Sell
95
-76
-44% -$48.9K ﹤0.01% 4048
2019
Q2 		$201K Sell
171
-43
-20% -$51.4K ﹤0.01% 3822
2019
Q1 		$265K Sell
214
-462
-68% -$529K ﹤0.01% 3836
2018
Q4 		$639K Sell
676
-895
-57% -$1.08M ﹤0.01% 3177
2018
Q3 		$2.26M Buy
1,571
+329
+26% +$498K ﹤0.01% 2776
2018
Q2 		$2M Sell
1,242
-152
-11% -$261K ﹤0.01% 2949
2018
Q1 		$2.26M Buy
1,394
+45
+3% +$93.6K ﹤0.01% 2781
2017
Q4 		$2.26M Sell
1,349
-1,249
-48% -$1.65M ﹤0.01% 2636
2017
Q3 		$3.63M Buy
2,598
+1,992
+329% +$2.34M ﹤0.01% 2114
2017
Q2 		$676K Sell
606
-378
-38% -$312K ﹤0.01% 3275
2017
Q1 		$533K Sell
984
-32
-3% -$19.6K ﹤0.01% 3046
2016
Q4 		$618K Buy
1,016
+323
+47% +$202K ﹤0.01% 3039
2016
Q3 		$495K Sell
693
-244
-26% -$187K ﹤0.01% 3194
2016
Q2 		$679K Sell
937
-119
-11% -$82K ﹤0.01% 3111
2016
Q1 		$629K Buy
1,056
+140
+15% +$71.8K ﹤0.01% 3085
2015
Q4 		$523K Buy
916
+16
+2% +$10.6K ﹤0.01% 3254
2015
Q3 		$503K Buy
900
+54
+6% +$39K ﹤0.01% 3356
2015
Q2 		$672K Buy
846
+265
+46% +$219K ﹤0.01% 3220
2015
Q1 		$483K Buy
581
+76
+15% +$59K ﹤0.01% 3316
2014
Q4 		$363K Buy
505
+451
+835% +$353K ﹤0.01% 3897
2014
Q3 		$37K Sell
54
-126
-70% -$102K ﹤0.01% 4991
2014
Q2 		$151K Sell
180
-25
-12% -$24.9K ﹤0.01% 4312
2014
Q1 		$334K Buy
+205
New +$248K ﹤0.01% 3575

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's CBIO Position: Q2 2021 in Review

Deutsche Bank sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 352 shares — an estimated $106K sold.

Deutsche Bank first reported a position in CBIO in Q1 2014 and held it in 29 quarters. The position peaked at $3.63M in Q3 2017. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • Deutsche Bank reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • Deutsche Bank sold 352 Crescent Biopharma shares in Q2 2021, an estimated $106K.
  • Deutsche Bank first reported a position in Crescent Biopharma in Q1 2014 and held it in 29 quarters.
  • Deutsche Bank's Crescent Biopharma position peaked at $3.63M in Q3 2017.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Deutsche Bank's 13F filing for Q2 2021, filed 11 Aug 2021.